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Trips and pharmaceuticals:
implications for India
Pradeep S. Mehta
1 On the post-Uruguay Round world trade scenario, after the accords in agriculture and
textiles and clothing, the Agreement on Trade-Related Aspects of Intellectual Property
Rights (TRIPs) is the issue affecting developing countries like India.
2 One of the seven intellectual properties covered under TRIPs is that of patents. It has
been the contentious issue for several reasons. India is committed to amend its patent
laws  by  the  year 2005  (for  technologies  previously  unprotected  in  its  market).  The
objective is to change the patent system which, in turn, is supposed to facilitate research
and development activities within the country.
3 This Briefing Paper examines the issue of patents and its impact on the pharmaceutical
industry in India, both foreign and Indian firms.
 
1. TRIPs, Pharmaceuticals and India: an Overview
4 According to the United Nations definition, a patent is a legally enforceable right, granted
by  a  country’s  government  to  an  inventor.  A  patent  excludes  other  persons  from
manufacturing, using or selling a patented product or from utilising a patented method
or process.
5 TRIPs covers seven types of intellectual property rights:
• trademarks
• trade secrets
• geographical indications
• industrial designs
• copyright
• integrated circuits, and
• patents
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6 Except in the sectors of food processing, pharmaceutical and agrochemicals the Indian
patent law is in conformity with the GATT provisions. In the aforementioned, only
process patents are allowed.
7 As  of  today,  India  has  a  process  patent  regime  regarding  phamaceutical  products.
Therefore, the 1970 Indian Patents Act has to be changed inorder to bring it in line with
the international laws on the patenting of pharmaceutical (and agrochemical) products.
8 Being a developing nation, India has a grace period of five years to change its patent laws
under the agreement on TRIPs. In other words, the 1970 Indian Patents Act will have to be
suitably amended by 31st December 1999.
9 At the same time, developing countries like India are given a grace period of ten years for
technologies  previously  unprotected in its  market.  During this  interim period of  ten
years,  all  patent applications will  be put in a « black box ».  However,  pharmaceutical
corporations can apply for an Exclusive Marketing Right (EMR) for their products for only
five years,  even  before  the  country  in  question  has  fully  phased  in  the  new  patent
protection system.
10 The proviso is that the product must have been registered for a patent and has received
marketing rights in any of the WTO member countries. Thus, it is a backdoor method for
granting monopoly rights. Furthermore, there is also a grey area here. If marketing rights
are granted for only five years, what will be its position over the five-year period, until
the country in question actually has amended its patent laws?
11 Transnational corporations (TNCs) control 90 % of all registered patents in the world. In
fact,  given such monopoly power over patents and the EMR clause,  India,  or for that
matter any developing country, does not have any transition period. This is true in the
case  of  protected  technology,  and  if  one  interprets  that  from  the  patent/product-
originating country angle. This is the haziest part of the TRIPs Agreement, with respect to
the pharmaceutical and also the agrochemicals sectors.
 
2. TRIPs and Pharmaceutical Industry in India
12 The existence of process patents under the 1970 Indian Patents Act resulted in a robust
growth of  domestic  pharmaceutical  industry  in India.  At  the  same time,  history  also
shows a decline in the business of foreign pharmaceutical companies in India (see Table 1
for Cross-Sectional Data and Table 2 for Trends).
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Table 1 - Sales and Share of Big Companies in Indian Market, 1992
Source: New Horizons in India, The Consequences of Pharmaceutical Patent Protection, Redwood H.
Oldwicks Press 1994.
 
Table 2 - Indian Pharmaceutical Market, 1970-1993
Unit: In Percent
Source: New Horizons in India, The Consequences of Pharmaceutical Patent Protection, Redwood H,
Oldwicks Press 1994.
13 Why is there such a paradox when the global business is expanding at a rapid pace? To
answer such a seemingly incongruous fact, one has to take the following into account:
• the 1970 Indian Patents Act was the instrument that made it possible for the domestic
pharmaceutical industry to expand rapidly:. because the Act legalised « reverse engineering »
of drugs that are patentable as products, throughout the industrialised world, but
unprotectable in India;
• well equipped with technological expertise, Indian scientists and businesses seized the
opportunity to do « reverse engineering » on therapeutically innovative drugs discovered
elsewere, and launched them on the domestic market as well as exporting them to other
countries, with similar gaps in their patent cover; and
• strategic abdication of many transnational corporations who refused to compete without
the patent cover. For example, the Sterling-Winthrop company wound up their business in
the 1970s and sold their shares to the Indian partner Dey’s Medical.
14 Furthermore, under the 1970 Indian Patents Act, the following points are relevant:
• no product patents are allowed in pharmaceutical, agrochemicals and food-processing
sectors, only process patents are admissible;
Trips and pharmaceuticals: implications for India
Annuaire suisse de politique de développement, 17 | 1998
3
• the Indian patent term of fourteen years from the date of filing for pharmaceutical
processes is curtailed to seven years from the date of filing, or five years from the date of
sealing a patent, whichever is shorter; and
• pharmaceutical process patents are automatically deemed to be endorsed a License of Right
for three years from the date of sealing a pharmaceutical patent.
15 With  the  coming  of  the  TRIPs  Agreement,  disputes  have  arisen  with  regard  to  the
protection of pharmaceutical patents. The main provisions of the TRIPs Agreement with
respect to pharmaceutical products are as follows:
• the minimum patent term will be twenty years from filing;
• patent protection is to be extended to pharmaceutical products;
• importation must be accepted as a working patent;
• compulsory licensing is relegated to special circumstances;
• in infringement suits, over process patents, the « burden of proof » is reversed;
• provide transitional arrangements – deferment of the acceptance of pharmaceutical product
patents by developing countries for ten years; and
• limited exclusivity is granted to developing countries for pharmaceutical products whose
patent applications are filed after the enforcement of the TRIPs Agreement.
 
3. Consequences of TRIPs: Myths and Reality
16 TRIPs does not provide for the retrospective patenting in India of drugs that are already
on the market or covered by existing patent applications elsewhere. Taking into account
the transitional period, there will be less impact on prices of new patented drugs on the
Indian market during the 1990s and only a minimal effect until 2005. Thereafter, it will
build  up  gradually  from  a  pool  of  new  drugs.  Global  progress,  in  research  and
development,  is  replenishing this  pool  at  a  steady but  moderate pace,  as  older  drug
patents expire (see Box 1).
Box 1 – Pharma-quake as Patents Expire
About 40 US drugs with $16bn sales in 1996 are set to loose patent protection by the
year 2002. This will throw the gate open for competition from generic drugs.
Cheaper drug price and bonanza for generic drugs will alter the research and
business of pharmaceutical majors.
To fill the patent gap, drug majors are turning more to biotechnology development
and other partners. The pressing needs for new drugs have led to the earlier
adoption of new technologies.
To avoid « Tagamat Crisis » (loss of patents), the companies are increasingly
investing in riskier, cutting-edge technologies. Smithkline-Beecham is one of the
first such companies to leap into new technologies for gene-hunting.
Again, Glaxo, after realising the futility of blockbluster dependency, is
contemplating to develop a broader « portfolio » of drugs. The rationale is to
minimise risks associated with the development of new drugs.
Source: Wall Street Journal, 13 August 1997.
17 Here,  one  has  to  consider  the  moderate  pace  of  pharmaceutical  innovation  and  of
obstacles to market penetration of new drugs in India. Such consideration leads to the
conclusion that, in value term, not more than 15% of the Indian market will be covered by
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patents  sometime  after 2005.  The  remaining  85% of  the  market  will  continue  to  be
exposed  to  the  impact  of  generic  competition.  Patented  products  will  themselves
ultimately contribute to that generic pool when their patents expire.
18 The time scale of the introduction of pharmaceutical patents in India under TRIPs makes
it certain that, if Indian drug prices rise during the remainder of the 1990s, it will not be
for patenting reasons. The earliest start of premium pricing for patented drugs will be in
the  early  years  of  the  next  decade.  No  significant  effect  can  be  anticipated  until
after 2005, because the weight of patented drugs on the Indian market will be too small
for economic impact.
19 More important than the time scale of patent protection will be fundamental « checks
and balances » which will slow down on the impact of premium pricing on Indian drug
expenditure (see Box 2). Such balances are as follows:
• the low purchasing power of Indian patents;
• Government price controls under permanent or reserve powers;
• therapeutic competition from cheaper unpatented drugs.
20 Of these the second is the most immediate, whereas the first and the third are the most
« durable » safeguards against a price explosion.
Box 2- Compulsory Licensing of Commercial Medicines Possible
According to the Coordinator of the Forum of Parliamentarians on Intellectual
Property, India, Mr. B.K. Keyala, compulsory licensing of pharmaceutical products
« for commercial purposes » is possible, within the ambit of the TRIPs Agreement.
Argued Keyala: « lndia should draw strength from Arts. 7 and 8 of TRIPs and insist on
compulsory licensing of pharmaceutical products for commercial purposes. »
The current understanding, under Art. 31 of the agreement, is that TRIPs provisions
only allow compulsory licensing for non-commercial use. However, Art. 7, which
outlines the objectives of the intellectual property agreement, states that
implementation of the agreement should inter alia « contribute to the transfer and
dissemination of technology ».
Furthermore, Art. 8 gives member countries the right to adopt measures to « protect
public health and nutritions and « promote public interest ».
India should Interpret these articles in the national interest since the constitutional
guarantee of the right to life encompasses the right to health, which requires
« availability of medicines at affordable prices », said Keyala.
Source: Press Trust of India, 26 December 1996.
21 Here it will be interesting to note that Canada established the Patented Medicine Prices
Review  Board  in 1987,  under  reforms  to  extend  patent  protection  to  brand-name
pharmaceuticals. Until recently, the Board reached over 100 settlements with the pharma
industry,  which  it  claims  has  saved  consumers  about C$110mn.  In  a  recent  case,  it
ordered a US company,  ICN Pharmaceutical’s  local  subsidiary,  to cut  the price of  its
Virazole by almost 90% and pay a penalty of C$1.2mn. Thus, there are precedents for such
price regulations.
22 There is,  nevertheless,  a  widespread belief  among Indian companies that  even if  the
remaining preconditions for R&D in India were met, they could not afford the cost of
minimum scale operations, and that only TNCs would be in a position to benefit.
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23 Evidently, TNCs have far greater financial resources, but they also have more diverse calls
on those resources and are themselves obliged to make difficult choices when it comes to
new R&D projects and facilities (see Table 3).
24 For TNCs, their challenge in India is whether the Indian authorities will  pursue their
declared  objective  of  attracting  global  investment  and  R&D  to India  by meeting  the
essential pre-conditions.
 
Table 3 - Available Revenue for R&D Activities
Unit: As percentage of sales
1. 8 out of 9 companies of the ﬁrst row.
Source: New Horizons in India, The Consequences of Pharmaceutical Patent Protection, Redwood H,
Oldwicks Press 1994.
 
4. Impact of TRIPs on Global Business
25 As expected, the proposed changes in the intellectual property regime are welcomed by
the  global  business  and  their  subsidiaries  operating  in  India.  Big TNCs  like  Hoechst,
Novartis, etc., have already set up 100% Indian subsidiaries. However, most of them are
interested  in  playing  a  waiting  game  regarding  their  involvement  in  the  Indian
pharmaceuticals market.
26 They are likely to introduce their new patented drugs once the system of product patent
becomes  fully  operational.  Even  in  that  case,  most  of  the  new drugs  will  either  be
imported as formulations or be formulated in India, by using imported bulk drugs. In
short, India is unlikely to be a site for R&D and production of bulk drugs.
27 For example, according to Glaxo-Wellcome, it is holding back on investments in India
because of concerns on Intellectual Property Rights (IPR). However, it plans to build up
volumes in certain therapeutic segments, by allowing their Indian subsidiary to negotiate
a cheaper price for imports from the parent company.
28 Under the TRIPs Agreement, India has to accept applications for the grant of product
patents from 1st January 1995. According to one estimate, up to July 1996, 264 applications
were received by the patent office.
29 Another area of concern is the pricing of drugs under the new patent regime. Though it is
a  fact  that  the  prices  of  Indian drugs  are  lower  than those  prevailing  in  developed
countries, the future price differential is unlikely to be large. The reason is to avoid any
action against the dumping of bulk drugs.
 
5. Impact of TRIPs on Indian Firms
30 Axiomatically,  the  introduction  of  product  patenting  will  affect  the  Indian
pharmaceutical firms to a large extent. Certainly, they will be prevented from taking a
Trips and pharmaceuticals: implications for India
Annuaire suisse de politique de développement, 17 | 1998
6
circuitous route to growth through the adoption of process patents. At the same time,
some of them are seriously concerned with the expansion of their business.
31 To achieve their aim, they are increasingly exploring the following options.
 
6. Development of New Drugs
32 A necessary condition is to increase the expenditure on R&D activities. Drug discovery
and development have to be included in the R&D strategy. In other words, the focus of
R&D will have to be changed from the innovation of new processes to the invention of
new products.
33 For example, Dr. Reddy’s Laboratory (a leading Indian manufacturer) has focused its R&D
expenditure  on  the  development  of  new  drugs  for  cancer,  bacterial  infections  and
diabetes. They have set up a research facility at the cost of Rs.8 crore (approximately
$2.3mn).
34 However, a couple of structural weaknesses have to be taken into account. First, given the
small  size of  Indian firms,  even a sharp increase in R&D activities  will  not  generate
sufficient funds for the development of new drugs. Secondly, Indian firms lack manpower
and other  institutional  mechanisms  to  launch new drugs  successfully  in  the  foreign
market.
35 Given such limitations, the focus on R&D should be on:
• the development of in-house drugs that have the same therapeutic value of those existing in
the market;
• the production of indigenous drugs, catering to the needs of India and other tropical
countries, where TNCs have little or no interest in introducing drugs according to their
needs.
 
7. Production of Off-Patent
36 A realistic assumption is that, in near future, off-patent drugs will emerge as one of the
important activity of Indian pharmaceutical firms.
37 Furthermore, off-patent (generic) drugs, made by the Indian firms, are going to meet
most  of  the  domestic  demand.  At  the  same  time,  it  is  incorrect  to  say  that  their
therapeutic value will be less than the new, on-patent drugs.
38 With the increasing concentration of Indian firms on generic drugs, its export prospects
are very high. Currently, the world market for generic drugs is $20 bn, and expected to
grow to $40 bn by 2005.  In order to take this  opportunity,  leading Indian firms (like
Ranbaxy,  SOL,  East  India  Pharmaceuticals)  are  building  their  capacities  to  produce
generic drugs.
39 For  example,  SOL  (Hyderabad)  has  set  up  a  separate  division  for  the  production  of
generics. Furthermore, it is expecting to generate more than 33% of its annual turnover
from generics. Exports of generics will get on further boost from foreign investment in
this area. US pharma giant Merck has set up a 100% subsidiary to produce and export
generics.
40 However,  Indian  firms  are  going  to  face  strong  competition  from  other  developing
countries, and even some developed countries. Therefore, the long run success of Indian
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firms depends on improved efficiency and exploration of new markets through South-
North and South-South cooperation, both at the producers’ and consumers’ levels.
 
8. Production of Patented Drugs under License
41 Global  drug  development  and  production  have  recently  been  undergoing  structural
changes. The reasons for such changes are:
• exponential increase in the cost of drug development;
• shortening of product life;
• stiff competition from generic drugs.
42 In order to gain maximum revenue within a short period, Indian firms are trying to get
licenses from global pharma business to produce and market on-patent drugs.
43 However, two discernible facts are worth mentioning:
• global pharma companies that do not have much stake in Indian market will not hesitate to
give licenses to Indian firms;
• companies with large subsidiaries in India (like Glaxo, Pfizer) are likely to introduce licensed
drugs through their subsidiaries only.
 
9. Marketing of Imported Drugs
44 The fourth option for Indian pharma firms is the marketing of imported drugs. Many
Indian  firms  are  interested  in  entering  into  long-term  arrangements  with  global
businesses. For example, Ranbaxy has entered into an alliance with Eli Lilly.
45 The new and liberalised drug policy has removed import restrictions from all but eight
category of drugs. Removal of import restrictions and proposed changes in IPR will lead
to an increase in drugs import.
 
10. TRIPs: Availability and Prices of Drugs
46 The aforementioned discussions on off-patent drugs reveal the fact that they will meet
most of the demands. Therefore, even under the new patent regime (compatible with the
TRIPs Agreement), the availability and prices of generic drugs will largely be unaffected.
47 However, the situation is different with respect to new (on-patent) drugs. There is no
doubt that these drugs will be available in the Indian market (either through production
or under license). But the effect on prices is ambiguous.
48 Under the customary theory of demand-supply,  the price level  should come down in
future. The reason is increased supply rather than increase in demand. Albeit, this ideal
situation may not be true in practice because of the following factors:
• the oligopolistic nature of global pharma business;
• the practice of transfer pricing by the global business, monitoring and regulation of prices
by the Government will be difficult;
• the price situation also depends on the proportion of patented drugs being sold in the Indian
market. At the same time, the global pharma business has a large number of patented drugs
that comes from their own R&D (see Table 4).
Trips and pharmaceuticals: implications for India
Annuaire suisse de politique de développement, 17 | 1998
8
49 Furthermore, in the long run, medical biotechnology is going to be the area of research
and development. Biotechnology base research of Indian firms (except the Government-
owned Central Drug Research Institute) is poor, and they are unlikely able to produce
many of these drugs.
 
Table 4 - R&D Position of World Pharmaceutical Majors, 1995
Source: Scrip, January 1996.
50 On the other hand, TNCs have a large base for research in medical biotechnology (see
Box 3). Given such a dominant position, prices of on-patent drugs are likely to go beyond
the reach of the consumers at large in the long run. Therefore,  the real  issue is not
availability of new drugs in the Indian market, but people’s access to them.
Box 3 - Hoechst Patents Ayurvedic Herb
Hoechst, Germany, patented the Indian medicinal plant Coleus Forskohlii, which is
being used for ayurvedic medicine.
Traditional uses of this herb include treatment for cardiovascular disease, abdominal
colic, respiratory disorders, painful urination, insomnia and convulsions.
In 1974, a large-scale screening of medicinal plants by the Central Drug Research
Institute of India revealed the blood pressure lowering and anti-spasmodic effects of
extracts from C. Forskohlii.
One of Hoechst’s patents covers a specific formula of the plant extract and its use in
treating cardiovascular disease and intraocular pressure.
According to a report by the Rural Advancement Foundation International, Canada,
in 1997, Hoechst will begin worlwide marketing of its C. Forskohlii derived drug.
Source: Press Trust of India, 20 February 1997
 
11. Conclusions
51 Given  such  a  hazy  scenario,  it  is  difficult  to  predict  the  future  of  the  Indian
pharmaceutical industry under the « new » regime of intellectual property rights and its
relationship with international trade. However, certain broad trends can be pictured.
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52 First of all Indian pharma companies are going to face stiff competition from the global
business, despite the fact that, at least in India, the pharma market is not oligopolistic. At
the same time, trends in research and development can make it so in the long run.
53 Therefore, Indian companies can either go for collaboration or concentrate on producing
and marketing generic drugs. This futuristic conclusion is based on a realistic assumption
which takes into consideration the poor research and market penetration strategies of
Indian companies.
54 On the other hand, global pharma majors are unlikely to consider India as one of their
bases  for  exploring  « new »  drugs  through  research.  At  the  most,  India  can  be  an
« assembly » point for some drugs.
55 The trickiest part is what position should the Indian government take regarding TRIPs
and its impact on pharmaceutical market. The issue is a political economic one, and has
to be approached from both angles – economics and politics.
56 Overall, the Government of India has two options:
• introduce an effective regulatory mechanism for « checks and balances » on the availability,
access and price of essential drugs;
• develop research facilities for the introduction of « new » drugs, catering to the needs of the
country.
57 Global  businesses  do  not  have  any  interest  in  developing  tropical  drugs.  Given  its
traditional  medicinal  plant  base,  India  can  take  a  leading  position  in  developing,
producing and exporting those drugs.
58 The drug policy of the government has to be a pro-active one – to take advantage of the
TRIPs regime. Compatibility between the above-mentioned two options serves as a base
for rational and need-based drug policy.
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